{"name":"Nektar Therapeutics","slug":"nektar-therapeutics","ticker":"","exchange":"","domain":"","description":"Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough.","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":307711000,"revenueGrowth":222.3,"grossMargin":0,"rdSpend":117330000,"netIncome":-164076000,"cash":280406000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"date":"2026-03-13","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxQOFJ4MFhtZFFKbTlfdzRIS2E2NDByN0Z5emNmX0VJeTRBdHJLN2ZrS1J6RllkZHR0WUtzYmRnNXh4SUhfRUtqTkM1NHJaNU9JM1FqaVJsMGowcEplZ0ZDUEotVXgxT2kteVpFSXNOSGhyaUh3M3k2TTdBWml1QjhraUZwQmRkVmJMQXc4cGJEVkhWb3ZIZ2RtbThjVFJEalZPblNKV3FvbnR3a0JUVWdYUkJqb3cydW9FMG5tblNuYmxvWmdqcFZJd2lQM1BQS1pobHVqaGJDM0tLdmJqeEk4RU1xY3M?oc=5","date":"2026-03-06","type":"pipeline","source":"Business Wire","summary":"Investor Notice: Robbins LLP Informs Investors of the Nektar Therapeutics Class Action Lawsuit - Business Wire","headline":"Investor Notice: Robbins LLP Informs Investors of the Nektar Therapeutics Class Action Lawsuit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNVEZLX1paYmREM3ZkQ0xELTdhbktzb2pSWmI3MEdpWG0takJXQ09BMU5URzBHTndubU9XazBkQUlMaWVDRHF6eDBCNVVsM1FZRFhCQWJLTUFOUmszSzFyTHNUemNTUGo0UmhrMk1BX2tBbDg5X00ySEJzTG5BQXl0a29wQnlPUXU5dkhsaWVHMF82a0szeVlYaEx3ZzdBTUxZYzRmQWxseHB4TDNQQkdrblNabw?oc=5","date":"2026-02-17","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"StockWatch: Nektar’s Rezpeg Sparks a Sweet “Comeback Story” - Genetic Engineering and Biotechnology News","headline":"StockWatch: Nektar’s Rezpeg Sparks a Sweet “Comeback Story”","sentiment":"neutral"},{"date":"2026-02-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQaHNyZWtjVnNRZzctdWE4VDVqNFRlR3oxSE05eGF0ZTB5aUFOTjhNYXc5VDJsUU9ib3NVZ2ozREpDWjhkUnpKZmhGQklhNXNGaUpUN0dwclFIY1kxS1l6bHRaaDh2Q3Q3ZmNtc2dJNnJoT1pIeGNGcVZ5U3BfMmV1VnBxeldPTnF0RWFQVXZuQQ?oc=5","date":"2026-01-08","type":"pipeline","source":"Yahoo Finance","summary":"Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics - Yahoo Finance","headline":"Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceutic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQX2xLdGNxbThTZUotMzM0V2oweEZkV3cyeTgwdGJVVDFuUlBhVWUxa29VMHFMamx1dTlkZEg3MFdmQ3NlZ19UQTRnOVBORzl3SVNwOS1JcG05Rmd4UTd0Sy02MHlNOGFKN2NRbFZVUF9UcnpMVVdUMmR1VzBVcEN6elJhbkJXeFB3R0R4ZXdqN3h1eXZqRUow?oc=5","date":"2026-01-05","type":"pipeline","source":"The Motley Fool","summary":"Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead - The Motley Fool","headline":"Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOZm8tcTVSU1h2NE9HT2p1dDM4aENTNWZ5WUNabnFzR25oZlB5Z3RqOHBmTDBvTUxSRVh1ZDdEMnNUeDY1LWJzNkpEdEZlbnhQeFJSa3lPOV8yWG9QU2N3Q1VtSmlmdFlhNlFBekhucUQ5Ym9uR1BKTkh0YU1zbmtQZ2dYOGJKRWRHb19IeEhWd3NPSW9NU3VqYnBCZjVIQkR5S1BLZUxLVTY0cUxYT1I2Tnc4QUdJaHJSVkZZMGxBS19NVUR2LXZB?oc=5","date":"2025-12-16","type":"trial","source":"Fierce Biotech","summary":"Nektar claims phase 2 alopecia success after excluding patients who 'should never have been enrolled' - Fierce Biotech","headline":"Nektar claims phase 2 alopecia success after excluding patients who 'should never have been enrolled'","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQX0QybHdMbEI5VGNYZ1dnaERnUFdpZGpWWERhZlFzS0VsSURTb1NQekxzczc5cjJsc1JZcnc3THp4SWtyQTZVcFVHb1lIUWt1cVR1dzMycWR2aEtPS3BfTzB2R3ZGYURWR0tWNTVuUjF2cnE1Y3pxMGphd19VWTBDeGlQeFpXMkNkVHJ4ejJiLV9HVUthTTZJRGlnQWVuU1gyRkxWLWJPOU9PSkIta2tNdllrVGhVZmY3eTd3VWRGRGJYQQ?oc=5","date":"2025-11-07","type":"earnings","source":"TradingView","summary":"Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y - TradingView","headline":"Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE92alBNTkxpbEZKTnJfYkJyVF9sWVNsQzRKZVFHYnNKYmttV2hJNktrMlBaeHZXR2ZDQmROYVlaSXNBQXMwM0ZaeUhKa1NMblNNcE1GeV9vLXVlaVVsM3VkeEhaUHJPcWFzNnQtS2x2WVpyWHhaWk90dmlBUlowUXM?oc=5","date":"2025-10-20","type":"deal","source":"BioSpace","summary":"Rumors of Eli Lilly Buyout Send Nektar’s Shares Spiking - BioSpace","headline":"Rumors of Eli Lilly Buyout Send Nektar’s Shares Spiking","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxOaWNWTWJRaFNOMlRDd25Dc1J6SnhYZHFxSllsTXF3N2tfWjFQaWdhai1ZcGVtYWRSNE5RNlZ0ZENVTXZ1a2JPdDhKM2luM0VJRnlaQVZKVmk0U05BU195TjRLWUhGbU1TZHdsY25tbUM5S1ZnWThtY2tzdFpuSlF2bVBycWxfZw?oc=5","date":"2025-06-26","type":"regulatory","source":"pharmaphorum","summary":"Nektar eyes pivotal trials for eczema drug cast off by Lilly - pharmaphorum","headline":"Nektar eyes pivotal trials for eczema drug cast off by Lilly","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOMzEwSmFkOGRpZTFDUl9QUWk1TnBxMzBNWHBQaGFoMmx2MVpQQmE3c0xQSzFmZy1tN0dLenIwRXV4UnMtQXExTHlDVkEtVUFsR0ZaT090V2ZiREhWRmU4Y1F4em1iZkpRZUZJa3d5bTYxT1d4YTBsaWc5WEQxSjV4RmwyYVNhRUNVaUF5WEY0SjlPSmFnWUdCZTg4eXJ5Vl84OFNqZThNRnhfeWJwNVl2MnRqbw?oc=5","date":"2025-06-24","type":"regulatory","source":"Investopedia","summary":"Nektar Therapeutics Stock Doubles After Promising Eczema Drug Trial Results - Investopedia","headline":"Nektar Therapeutics Stock Doubles After Promising Eczema Drug Trial Results","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":307711000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":307711000,"period":"2017-12-31"},{"value":95466000,"period":"2017-12-31"},{"value":152928000,"period":"2017-09-30"},{"value":34589000,"period":"2017-06-30"},{"value":24728000,"period":"2017-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":117330000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-164076000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":280406000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}